Synapse - Shanu Modi

Results (21)

Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients

Meeting Abstract

Pusztai, L.; Lu, H.; Hale, C.; Grosse-Wilde, A.; Specht, J.; Modi, S.; Han, H.; Cortes, J.; Oliveira, M.; Garfin, P.; more...
Journal for ImmunoTherapy of Cancer (2020)

Fulltext@MSK | Save

Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors

Journal Article

Razavi, P.; Dickler, M. N.; Shah, P. D.; Toy, W.; Brown, D. N.; Won, H. H.; Li, B. T.; Shen, R.; Vasan, N.; Modi, S.; more...
Nature Cancer (2020)

Fulltext@MSK | Save

Phase Ib dose-escalation/expansion trial of ribociclib in combination with everolimus and exemestane in postmenopausal women with HR(+), HER2(-) advanced breast cancer

Journal Article

Bardia, A.; Modi, S.; Oliveira, M.; Cortes, J.; Campone, M.; Ma, B.; Dirix, L.; Weise, A.; Hewes, B.; Diaz-Padilla, I.; more...
Clinical Cancer Research (2020)

Fulltext@MSK | Save

Trastuzumab deruxtecan (T-DXd, DS-8201) in HER2-positive metastatic breast cancer previously treated with T-DM1: DESTINY-Breast01 study

Meeting Abstract

Krop, I.; Manich, C. S.; Yamashita, T.; Park, Y. H.; Kim, S. B. K.; Tamura, K.; Andre, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; more...
Swiss Medical Weekly (2020)

Fulltext@MSK | Save

A phase 3, multicenter, randomized, open-label trial of trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04)

Meeting Abstract

Zaman, K.; Modi, S.; Ohtan, S.; Lee, C.; Wang, Y.; Saxena, K.; Cameron, D. A.
Swiss Medical Weekly (2020)

Fulltext@MSK | Save

Measuring tumor epichaperome expression using [(124)I] PU-H71 positron emission tomography as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2-negative metastatic breast cancer

Journal Article

Jhaveri, K. L.; dos Anjos, C. H.; Taldone, T.; Wang, R.; Comen, E.; Fornier, M.; Bromberg, J. F.; Ma, W.; Patil, S.; Rodina, A.; more...
JCO Precision Oncology (2020)

Fulltext@MSK | Save

A phase I study of DLYE5953A, an anti-LY6E antibody covalently linked to monomethyl auristatin E, in patients with refractory solid tumors

Journal Article

Tolaney, S. M.; Do, K. T.; Eder, J. P.; LoRusso, P. M.; Weekes, C. D.; Chandarlapaty, S.; Chang, C. W.; Chen, S. C.; Nazzal, D.; Schuth, E.; more...
Clinical Cancer Research (2020)

Fulltext@MSK | Save

Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis

Meeting Abstract

Modi, S.; Andre, F.; Krop, I. E.; Saura, C.; Yamashita, T.; Kim, S. B.; Tamura, K.; Chen, S.; Suto, F.; Kuwahara, Y.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Prevalence and characterization of dermatologic adverse events related to alpelisib (BYL719) in breast cancer patients

Meeting Abstract

Barrios, D. M.; Wang, D. G.; Blinder, V. S.; Bromberg, J.; Drullinsky, P.; Funt, S. A.; Jhaveri, K. L.; Lake, D.; Lyons, T.; Modi, S.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies

Meeting Abstract

Powell, C. A.; Camidge, D. R.; Modi, S.; Qin, A.; Taitt, C.; Lee, C.; Hackshaw, M. D.; Singh, J.; Iwata, H.
Annals of Oncology (2020)

Fulltext@MSK | Save